Recro Pharma Inc expected to post a loss of 7  cents a share - Earnings Preview

Societal CDMO

26/02/2022 02:36

* Recro Pharma Inc  REPH.OQ   REPH.O  is expected to show a
rise
in quarterly revenue when it reports  results on March 1. 
    * The Exton Pennsylvania-based  company is expected to
report  a
116.0% increase in revenue to $21.412 million from $9.91 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Recro Pharma Inc is
for a
loss of 7 cents per share. For the same quarter last year, the
company reported a loss of 48 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Recro
Pharma Inc
is $5.5​, about 70.4% above​ its last closing price
of $1.63. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.07       -0.07      -0.07     Met     4.5
 Jun. 30 2021  -0.11       -0.11      0.03      Beat    127.3
 Mar. 31 2021  -0.25       -0.25      -0.23     Beat    9.8​
 Dec. 31 2020  -0.25       -0.22      -0.48     Missed  -118.2
 ​​Sep.        -0.21       -0.20      -0.09     Beat    56.1
 30 2020                                                
 Jun. 30 2020  -0.17       -0.16      -0.25     Missed  -56.2​
 Mar. 31 2020  -0.02       -0.03      -0.33     Missed  -890.1
 Dec. 31 2019  -0.22       -0.25      0.61      Beat    341.6
 This summary was machine generated February 26 at 02:36 GMT. 
All figures in US dollars  unless otherwise stated